The prevalence of erectile dysfunction increases with age. It has been estimated that the worldwide prevalence of erectile dysfunction will be 322 million cases by the year 2025. Erectile dysfunction was once considered to be psychogenic in origin and was frequently neglected by healthcare providers. Recently, many physiological causes of this condition have been identified and there is potential for therapy to improve a patient’s quality of life, self-esteem and ability to maintain intimate relationship. Now medical therapy with oral agents is generally the first-line treatment option in men presenting with erectile dysfunction.

Ajanta Pharma has a significant global presence in the Male Erectile Dysfunction segment (MED) through its key brand ‘Kamagra’ (Sildenafil Citrate). The brand has presence in more than 13 countries around the world. Ajanta was the 1st company in the world to introduce Sildenafil Citrate in Jelly form, which was also accepted well for its dosage convenience. This was followed by the launch of Kamagra Chewable Tablets and also Kamagra Effervescent Tablets. These compositions have been developed in various flavours to ensure patient convenience. The product (generic) has received marketing authorization in 11 EU countries under the DCP (Decentralized Procedure).